Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

10
69
2
4

Year Published

2015
2015
2021
2021

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 88 publications
(85 citation statements)
references
References 40 publications
10
69
2
4
Order By: Relevance
“…An earlier study reported that glucose tolerance is not impaired in MS patients [10]. On the contrary, Wens et al demonstrated that MS patients are at increased risk to develop impaired glucose tolerance [39].…”
Section: Discussionmentioning
confidence: 95%
See 1 more Smart Citation
“…An earlier study reported that glucose tolerance is not impaired in MS patients [10]. On the contrary, Wens et al demonstrated that MS patients are at increased risk to develop impaired glucose tolerance [39].…”
Section: Discussionmentioning
confidence: 95%
“…It has been postulated that MS may be associated with metabolic derangement, leading to obesity [9]. Moreover, insulin resistance may be associated with the extent of disability, as estimated by the Expanded Disability Status Scale (EDSS) [10].…”
Section: Introductionmentioning
confidence: 99%
“…Recently, increased prevalence of insulin resistance and impaired glucose tolerance in MS patients was reported (Oliveira et al, 2014; Penesova et al, 2015; Wens et al, 2013). In previous studies, IL-17A inhibited adipogenesis and moderated adipose tissue accumulation in vitro and IL-17a −/− mice showed increased bodyweight, glucose tolerance and insulin sensitivity (Ahmed and Gaffen, 2010; Ahmed and Gaffen, 2013; Straus, 2013; Winer et al, 2009; Zuniga et al, 2010).…”
Section: Discussionmentioning
confidence: 99%
“…The compounds that can readily cross the BBB include:simvastatin, atorvastatin, cerivastatin, pravastatin and rosuvastatin (87). Exendin-4 and GLP-1 have been shown to reduce inflammation, demyelination and cytokine release in various animal models of MS (88). Most glucagon-like peptide-1 (GLP-1) mimetics such as exendin-4, liraglutide, and lixisenatide cross the BBB and show neuroprotective effects in many studies.…”
Section: New Possibilities In the Treatment Of Ms-neuroprotectionmentioning
confidence: 99%